(Q29617451)

PubMed

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=15711537

30 April 2017

1 reference

ChEBI release 2020-05-28

Fabian MA

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=15711537

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=15711537

30 April 2017

Biggs WH 3rd

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=15711537

30 April 2017

Treiber DK

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=15711537

30 April 2017

Atteridge CE

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=15711537

30 April 2017

Azimioara MD

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=15711537

30 April 2017

Benedetti MG

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=15711537

30 April 2017

Carter TA

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=15711537

30 April 2017

Ciceri P

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=15711537

30 April 2017

Edeen PT

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=15711537

30 April 2017

Floyd M

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=15711537

30 April 2017

Ford JM

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=15711537

30 April 2017

Galvin M

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=15711537

30 April 2017

Gerlach JL

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=15711537

30 April 2017

Grotzfeld RM

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=15711537

30 April 2017

Herrgard S

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=15711537

30 April 2017

Insko DE

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=15711537

30 April 2017

Insko MA

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=15711537

30 April 2017

Lai AG

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=15711537

30 April 2017

Lélias JM

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=15711537

30 April 2017

Mehta SA

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=15711537

30 April 2017

Milanov ZV

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=15711537

30 April 2017

Velasco AM

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=15711537

30 April 2017

Wodicka LM

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=15711537

30 April 2017

Patel HK

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=15711537

30 April 2017

Zarrinkar PP

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=15711537

30 April 2017

Lockhart DJ

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=15711537

30 April 2017

language of work or name

1 reference

30 April 2017

publication date

March 2005

1 reference

PubMed

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=15711537

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=15711537

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=15711537

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=15711537

30 April 2017

page(s)

329-36

1 reference

PubMed

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=15711537

Protein kinases--the major drug targets of the twenty-first century?

30 April 2017

cites work

1 reference

The protein kinase complement of the human genome

1 May 2017

1 reference

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 May 2017

1 reference

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 May 2017

1 reference

A protein kinase involved in the regulation of inflammatory cytokine biosynthesis

1 May 2017

1 reference

A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket

1 May 2017

1 reference

Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site

1 May 2017

1 reference

Structural basis for p38alpha MAP kinase quinazolinone and pyridol-pyrimidine inhibitor specificity

1 May 2017

1 reference

Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors

1 May 2017

1 reference

SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase

1 May 2017

1 reference

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 May 2017

1 reference

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 May 2017

1 reference

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

1 May 2017

1 reference

The specificities of protein kinase inhibitors: an update

1 May 2017

1 reference

Overriding imatinib resistance with a novel ABL kinase inhibitor

1 May 2017

1 reference

Issues and progress with protein kinase inhibitors for cancer treatment

1 May 2017

1 reference

7 January 2021

Display cloning: functional identification of natural product receptors using cDNA-phage display

1 reference

7 January 2021

p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases

1 reference

7 January 2021

An efficient proteomics method to identify the cellular targets of protein kinase inhibitors.

1 reference

7 January 2021

Different susceptibility of protein kinases to staurosporine inhibition. Kinetic studies and molecular bases for the resistance of protein kinase CK2

1 reference

7 January 2021

Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer

1 reference

7 January 2021

Combinatorial chemoprevention of intestinal neoplasia

1 reference

7 January 2021

CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML).

1 reference

7 January 2021

Kinomics-structural biology and chemogenomics of kinase inhibitors and targets

1 reference

7 January 2021

Perspectives on the development of a molecularly targeted agent

1 reference

7 January 2021

BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study

1 reference

7 January 2021

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

1 reference

7 January 2021

Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias.

1 reference

7 January 2021

High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

1 reference

7 January 2021

Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL.

1 reference

7 January 2021

Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop

1 reference

7 January 2021

Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases

1 reference

7 January 2021

Optimization of 2-phenylaminoimidazo[4,5-h]isoquinolin-9-ones: orally active inhibitors of lck kinase

1 reference

7 January 2021

Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo

1 reference

7 January 2021

The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations

1 reference

7 January 2021

Novel agents in the treatment of lung cancer: conference summary statement

1 reference

7 January 2021

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=15711537

Identifiers

2 references

30 April 2017

Consolidated OpenCitations Corpus – April 2017

Dimensions Publication ID

1036157274

0 references

1 reference

Consolidated OpenCitations Corpus – April 2017

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=15711537

PubMed publication ID

2 references

30 April 2017

Consolidated OpenCitations Corpus – April 2017